BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

45 related articles for article (PubMed ID: 29356683)

  • 21. Co-expression network-based identification of biomarkers correlated with the lymph node metastasis of patients with head and neck squamous cell carcinoma.
    Jin Y; Qin X
    Biosci Rep; 2020 Feb; 40(2):. PubMed ID: 32076707
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting forkhead box M1 transcription factor in breast cancer.
    O'Regan RM; Nahta R
    Biochem Pharmacol; 2018 Aug; 154():407-413. PubMed ID: 29859987
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The expression and clinical significance of secretory leukocyte proteinase inhibitor (SLPI) in mammary carcinoma using bioinformatics analysis.
    Xie W; Zhang H; Qin S; Zhang J; Fan X; Yin Y; Liang R; Long H; Yi W; Fu D; Ma C; Lv M; Yu F
    Gene; 2019 Dec; 720():144088. PubMed ID: 31476404
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells.
    Hamurcu Z; Ashour A; Kahraman N; Ozpolat B
    Oncotarget; 2016 Mar; 7(13):16619-35. PubMed ID: 26918606
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The secretory leukocyte protease inhibitor (SLPI) suppresses cancer cell invasion but promotes blood-borne metastasis via an invasion-independent pathway.
    Sugino T; Yamaguchi T; Ogura G; Kusakabe T; Goodison S; Homma Y; Suzuki T
    J Pathol; 2007 Jun; 212(2):152-60. PubMed ID: 17455170
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FOXM1 transcriptionally regulates expression of integrin β1 in triple-negative breast cancer.
    Hamurcu Z; Kahraman N; Ashour A; Ozpolat B
    Breast Cancer Res Treat; 2017 Jun; 163(3):485-493. PubMed ID: 28361350
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased secretory leukocyte protease inhibitor (SLPI) production by highly metastatic mouse breast cancer cells.
    Sayers KT; Brooks AD; Sayers TJ; Chertov O
    PLoS One; 2014; 9(8):e104223. PubMed ID: 25110884
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Secretory leukocyte protease inhibitor (SLPI) as a potential target for inhibiting metastasis of triple-negative breast cancers.
    Kozin SV; Maimon N; Wang R; Gupta N; Munn L; Jain RK; Garkavtsev I
    Oncotarget; 2017 Dec; 8(65):108292-108302. PubMed ID: 29312532
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FOXM1 regulates proliferation, senescence and oxidative stress in keratinocytes and cancer cells.
    Smirnov A; Panatta E; Lena A; Castiglia D; Di Daniele N; Melino G; Candi E
    Aging (Albany NY); 2016 Jul; 8(7):1384-97. PubMed ID: 27385468
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells.
    Anders L; Ke N; Hydbring P; Choi YJ; Widlund HR; Chick JM; Zhai H; Vidal M; Gygi SP; Braun P; Sicinski P
    Cancer Cell; 2011 Nov; 20(5):620-34. PubMed ID: 22094256
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transcription factor FOXM1c is repressed by RB and activated by cyclin D1/Cdk4.
    Wierstra I; Alves J
    Biol Chem; 2006 Jul; 387(7):949-62. PubMed ID: 16913845
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Secretory leukocyte protease inhibitor mediates proliferation of human endometrial epithelial cells by positive and negative regulation of growth-associated genes.
    Zhang D; Simmen RC; Michel FJ; Zhao G; Vale-Cruz D; Simmen FA
    J Biol Chem; 2002 Aug; 277(33):29999-30009. PubMed ID: 12023969
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SLPI: a new target for stopping metastasis.
    Munn LL; Garkavtsev I
    Aging (Albany NY); 2018 Jan; 10(1):13-14. PubMed ID: 29356683
    [No Abstract]   [Full Text] [Related]  

  • 34. FOXM1 (Forkhead box M1) in tumorigenesis: overexpression in human cancer, implication in tumorigenesis, oncogenic functions, tumor-suppressive properties, and target of anticancer therapy.
    Wierstra I
    Adv Cancer Res; 2013; 119():191-419. PubMed ID: 23870513
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.